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Molecular identification of aspartate N-acetyltransferase and its
mutation in hypoacetylaspartia
Abstract
The brain-specific compound NAA (N-acetylaspartate) occurs almost exclusively in neurons, where its
concentration reaches approx. 20 mM. Its abundance is determined in patients by MRS (magnetic
resonance spectroscopy) to assess neuronal density and health. The molecular identity of the NAT
(N-acetyltransferase) that catalyses NAA synthesis has remained unknown, because the enzyme is
membrane-bound and difficult to purify. Database searches indicated that among putative NATs (i.e.
proteins homologous with known NATs, but with uncharacterized catalytic activity) encoded by the
human and mouse genomes two were almost exclusively expressed in brain, NAT8L and NAT14.
Transfection studies in HEK-293T [human embryonic kidney-293 cells expressing the large T-antigen
of SV40 (simian virus 40)] indicated that NAT8L, but not NAT14, catalysed the synthesis of NAA from
L-aspartate and acetyl-CoA. The specificity of NAT8L, its Km for aspartate and its sensitivity to
detergents are similar to those described for brain Asp-NAT. Confocal microscopy analysis of CHO
(Chinese-hamster ovary) cells and neurons expressing recombinant NAT8L indicates that it is associated
with the ER (endoplasmic reticulum), but not with mitochondria. A mutation search in the NAT8L gene
of the only patient known to be deficient in NAA disclosed the presence of a homozygous 19 bp
deletion, resulting in a change in reading frame and the absence of production of a functional protein.
We conclude that NAT8L, a neuron-specific protein, is responsible for NAA synthesis and is mutated in
primary NAA deficiency (hypoacetylaspartia). The molecular identification of this enzyme will lead to
new perspectives in the clarification of the function of this most abundant amino acid derivative in
neurons and for the diagnosis of hypoacetylaspartia in other patients.
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The brain-specific compound NAA (N-acetylaspartate) occurs
almost exclusively in neurons, where its concentration reaches
approx. 20 mM. Its abundance is determined in patients by
MRS (magnetic resonance spectroscopy) to assess neuronal
density and health. The molecular identity of the NAT (N-acetyl-
transferase) that catalyses NAA synthesis has remained unknown,
because the enzyme is membrane-bound and difficult to purify.
Database searches indicated that among putative NATs (i.e.
proteins homologous with known NATs, but with uncharacterized
catalytic activity) encoded by the human and mouse genomes
two were almost exclusively expressed in brain, NAT8L and
NAT14. Transfection studies in HEK-293T [human embryonic
kidney-293 cells expressing the large T-antigen of SV40 (simian
virus 40)] indicated that NAT8L, but not NAT14, catalysed
the synthesis of NAA from L-aspartate and acetyl-CoA. The
specificity of NAT8L, its Km for aspartate and its sensitivity
to detergents are similar to those described for brain Asp-NAT.
Confocal microscopy analysis of CHO (Chinese-hamster ovary)
cells and neurons expressing recombinant NAT8L indicates that
it is associated with the ER (endoplasmic reticulum), but not with
mitochondria. A mutation search in the NAT8L gene of the only
patient known to be deficient in NAA disclosed the presence of
a homozygous 19 bp deletion, resulting in a change in reading
frame and the absence of production of a functional protein. We
conclude that NAT8L, a neuron-specific protein, is responsible
for NAA synthesis and is mutated in primary NAA deficiency
(hypoacetylaspartia). The molecular identification of this enzyme
will lead to new perspectives in the clarification of the function of
this most abundant amino acid derivative in neurons and for the
diagnosis of hypoacetylaspartia in other patients.
Key words: endoplasmic reticulum (ER), hypoacetylaspartia,
membrane protein, N-acetylaspartate (NAA), N-acetyltransferase
(NAT).
INTRODUCTION
NAA (N-acetylaspartate), a brain-specific molecule discovered
more than 50 years ago, is the second most abundant metabolite
in brain after glutamate. It is essentially present in neurons,
where its concentration reaches approx. 20 mM. Its abundance
can be determined by MRS (magnetic resonance spectroscopy) to
monitor neuronal density and health in neurological disorders,
including Alzheimer’s disease, multiple sclerosis and AIDS
encephalopathy [1]. NAA is formed from aspartate and acetyl-
CoA by Asp-NAT (aspartate N-acetyltransferase), a membrane-
bound enzyme [2–4], which is unstable in the presence of
detergents [5] and could therefore not be purified. Its subcellular
localization has been variously reported as mitochondrial [6,7]
or microsomal [4,8]. NAA is not degraded in neurons, but it
is transferred, by an undefined mechanism, to oligodendrocytes,
the myelin-forming cells, where it is hydrolysed by ASPA
(aspartoacylase, also known as aminoacylase II). The acetate
released in this process serves as a precursor for the synthesis
of fatty acids, which are required for the formation of
myelin lipids [9]. NAA serves also as a precursor for N-
acetylaspartylglutamate [10,11], the most abundant dipeptide
present in brain and possibly a neurotransmitter [12]. Other
proposed roles for NAA are osmoregulation or disposal of amino
groups resulting from glutamate transamination [1]. It is accepted
that NAA does not appear to be a neurotransmitter [13], but
to date no agreement exists on the relative importance of the
other potential roles.
NAA metabolism is disrupted in two inborn errors of
metabolism. Deficiency of aspartoacylase, caused by mutations
in the ASPA gene, gives rise to a leucodystrophy known as
Canavan disease [OMIM (Online Mendelian Inheritance in Man)
accession number 271900], which is characterized by onset
in early infancy, dystonia, severe mental defects, blindness,
megalencephaly and death, on average, by 18 months [14]. NAA
concentration is raised in brain, CSF (cerebrospinal fluid) and
urine. The ‘opposite’ disorder, i.e. the absence of brain NAA, has
been described in only one patient, with truncal ataxia, marked
developmental delay, seizures and secondary microcephaly [15–
17]. This disorder, designated ‘hypoacetylaspartia’, is presumably
due to a deficiency of Asp-NAT, but this has not been
demonstrated.
Abbreviations used: ASPA, aspartoacylase; Asp-NAT, aspartate N-acetyltransferase; CHO, Chinese-hamster ovary; DMEM, Dulbecco’s modified Eagle’s
medium; ER, endoplasmic reticulum; FBS, fetal bovine serum; HA, haemagglutinin; HEK-293T; human embryonic kidney-293 cells expressing the large
T-antigen of SV40 (simian virus 40); MRS, magnetic resonance spectroscopy; MAP-2, microtubule-associated protein-2; NAA, N-acetylaspartate; NAT,
N-acetyltransferase; P44, peptide 44 of mouse NAT8L; P45, peptide 45 of mouse NAT8L; PDI, protein disulfide isomerase; PDIb, PDI domain b; Pfu,
Pyrococcus furiosus.
1 To whom correspondence should be addressed (email emile.vanschaftingen@uclouvain.be).
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A better definition of the role of NAA and the identification
of the defect underlying hypoacetylaspartia would greatly benefit
from the molecular identification of Asp-NAT. This identification
was the purpose of the present work.
EXPERIMENTAL
Preparation of expression vectors
Human and mouse total brain cDNA were synthesized with
random primers and 1.5–2.5 μg of total RNA with the M-
MuLV (Moloney murine leukaemia virus) reverse transcriptase
(Fermentas) according to the manufacturer’s instructions.
FirstChoice® human brain total RNA was from Applied
Biosystems, and mouse total brain RNA was prepared as described
in [18].
The open reading frames of mouse NAT14 (GenBank® ref-
erence sequence NM_201355) and mouse NAT8L (GenBank®
reference sequence NM_001001985) were PCR-amplified using
2.5 units of Pwo (Pyrococcus woesei) polymerase (Roche
Applied Science) in the presence of 1.5 M betaine (Sigma–
Aldrich) with mouse total brain cDNA as a template. For the
untagged constructions, a 5′-primer (for primer sequences see
Supplementary Table S1 available at http://www.BiochemJ.org/
bj/425/bj4250127add.htm), containing the putative ATG preceded
by a perfect Kozak sequence and a KpnI site, and a 3′-primer,
containing the putative stop codon flanked by a XbaI site, were
used. For the C-terminally tagged constructs, the 5′-primers were
the same, but the putative stop codon in the 3′-primers was
mutated and flanked by a XbaI site. For the N-terminally tagged
constructs, the 5′-primers were devoid of Kozak sequence and
the 3′-primers were the same as for the wild-type amplifications.
The PCR amplifications started with an initial denaturation step
at 96 ◦C for 3 min, followed by 35 cycles for 30 s at 96 ◦C,
1 min at 60 ◦C and 1 min at 72 ◦C, with a final extension step
at 72 ◦C for 5 min. All PCRs reported in the present study were
performed with this five-step program except for site-directed
mutagenesis (see below). PCR products of the expected size were
obtained, subcloned into the pBlueScript plasmid (Invitrogen)
and checked by sequencing. The KpnI/XbaI-digested products
were prepared from the Escherichia coli XL1blue strain (C-
terminally tagged constructs) or from E. coli JM110 strain (wild-
type and N-terminally tagged constructs) and inserted in pCMV5,
pEF6MycHisA and pEF6HisB expression vectors (Invitrogen)
for the wild-type, C-terminally tagged and N-terminally tagged
constructs respectively. For human NAT8L, amplifications were
performed with 2.5 units of Pfu (Pyrococcus furiosus) polymerase
(Fermentas), in the presence of 1 M betaine, with 2 μl of human
total brain cDNA as a template. The three types of construct were
prepared as for the mouse sequences and checked by sequencing.
Site-directed mutagenesis
pBlueScript vector (50 ng) containing the human NAT8L
sequence, designed to be expressed with a His6 tag at its
C-terminus, was used as a template in a 50 μl PCR mixture
[25 pmol of each primer (see Supplementary Table S1), 0.2 mM
dNTP, 1 M betaine and 2.5 units of Pfu polymerase in 1× Pfu
buffer]. All these primers were phosphorylated at their 5′ end.
This mixture was subjected to thermal cycling at 96 ◦C for 30 s
for denaturation, followed by 30 s at 55 ◦C for annealing and
5 min at 72 ◦C for extension. A total of 20 cycles was used and the
procedure was ended by 7 min at 72 ◦C. For both mutants, three
identical reactions were performed and the products were pooled
at the purification step in 35 μl of 10 mM Tris/HCl, pH 8.5. The
purified PCR product (30 μl) was incubated overnight at 16 ◦C
with 5 units of T4 DNA ligase (Fermentas) in the presence of
5% (v/v) PEG [poly(ethylene glycol)] 4000 in 50 μl of 1× ligase
buffer (Fermentas). The ligation product was then digested for
2 h at 37 ◦C with 20 units of DpnI in order to eliminate the wild-
type template. Aliquots (15 μl) of this mixture were then used
to transform 100 μl of E. coli XL1blue bacteria. The complete
NAT8L coding region of all plasmids was sequenced to verify the
presence of the introduced deletion and the absence of random
mutations. The KpnI/XbaI fragment was then subcloned into the
pEF6MycHisA vector and both mutants were expressed as His6-
and Myc-tagged fusion proteins.
Transfections of HEK-293T cells and Western blot analysis
HEK-293T cells [human embroynic kidney-293 cells expressing
the large T-antigen of SV40 (simian virus 40)] were cultured
and transfected essentially as described by Rzem et al. [19]
using the jetPEITM procedure. After 48 h at 37 ◦C, the cells
were washed once with 5 ml of cold PBS. They were scraped
into 0.8 ml of extraction buffer (20 mM Hepes, pH 7.1, 5 μg/ml
leupeptin and 5 μg/ml antipain), frozen in liquid nitrogen, thawed
and lysed by vortex-mixing. The extracts were incubated with
100 units/ml DNase I prepared in 5 mM MgSO4 (Sigma–Aldrich)
for 1 h on ice before use. Protein concentration was determined
with the Bradford assay [20], using γ -globulin as a standard.
Western blots were performed as described previously [19] with a
monoclonal anti-His6 antibody (PentaHis antibody from Qiagen)
diluted 1:2000 in PBS containing 1% (w/v) BSA. After washing,
membranes were probed for 1 h at room temperature (22 ◦C)
with peroxidase-conjugated anti-(mouse Ig) antibody (Sigma–
Aldrich). Detection was performed using the ECL (enhanced
chemiluminescence) Western blot analysis system from GE
Healthcare according to the manufacturer’s protocol.
NAA measurements by isotope dilution GC–MS
Quantification of NAA in cell medium was performed by GC–
MS as described by Kelley and Stamas [21] with N-[2H3]-
acetylaspartate (provided by Dr H.J. ten Brink, VU Medical
Center, Amsterdam, The Netherlands). Samples (0.2 ml) were
treated with hydroxylamine hydrochloride in the presence of
N-[2H3]-acetylaspartate, as the internal standard, and extracted
with ethyl acetate followed by diethyl ether. After evaporation
of the combined extracts under a stream of nitrogen,
the residue was resuspended in acetonitrile and derivatiz-
ation was achieved with a BSTFA/TMCS [N,O-bis(trime-
thylsilyl)trifluoroacetamide/trimethylchlorosilane; 99:1] mixture.
Analysis was performed by GC using a Hewlett-Packard 6890
series GC system equipped with a 30 m × 0.25 mm fused silica
capillary column (CP-SIL 8CB; Varian), with helium as the carrier
gas, coupled with a Hewlett-Packard 5973 mass-selective detector
under electron-impact fragmentation. Mass spectrometric data
were collected in the selected-ion mode at m/z = 274 for native
NAA and m/z = 277 for the synthetic isotopic NAA. Calibration
curves were constructed by mixing 4.5 μg of the isotopic NAA
with standard solution containing 0–6 μg of NAA, followed by
drying under nitrogen and direct derivatization with the silylating
agent.
Assay of Asp-NAT
Asp-NAT was assayed radiochemically in a mixture (200 μl final
volume) comprising, unless otherwise stated, 10 mM potassium
phosphate, 20 mM Hepes, pH 7.1, 1 mM MgCl2, 50 μM
L-aspartate, 105 c.p.m. L-[U-14C]aspartate (GE Healthcare),
c© The Authors Journal compilation c© 2010 Biochemical Society
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200 μM acetyl-CoA (Sigma–Aldrich) and 10 μl of a cell extract
containing approx. 5–10 mg of protein/ml. After 20–40 min at
30 ◦C, the reaction was stopped by a 5-min incubation at 80 ◦C
and 1 ml of 5 mM Hepes, pH 7.1, was added. The sample was
centrifuged for 5 min at 16000 g and the supernatant was applied
on to a 1 ml Dowex AG1X8 column (Cl− form, 100–200 mesh;
Acros Organics) prepared in a Pasteur capillary pipette. The
latter was washed with 2 ml of 5 mM Hepes, pH 7.1, followed
by 5 ml of 150 mM NaCl in the same buffer, to elute unreacted
aspartate, and 5 ml of 300 mM NaCl, to elute NAA. Radioactivity
was counted in the presence of Ultima GoldTM (PerkinElmer)
in a liquid-scintillation counter. The kinetic studies shown in
Figure 3 and Supplementary Figures S2–S4 were performed
using washed pellets, obtained by centrifuging extracts for 20 min
at 16000 g, resuspending the pellets in the initial volume of
extraction buffer, recentrifuging the preparation under similar
conditions, and resuspending the final pellets in the original
volume of extraction buffer.
Mutation search
All experiments with human DNA have been performed in
accordance with the Declaration of Helsinki (2000) of the World
Medical Association and have been approved by the Ethical
Committee of the Faculty of Medicine of University of Louvain.
Genomic DNA analysis of the child with hypoacetylaspartia [16]
was performed with informed consent of the legal parents. The
three exons of the NAT8L gene were PCR-amplified using 0.5 μM
forward and reverse primers (see Supplementary Table S1) with
75 ng of genomic DNA as a template. These reactions (50 μl)
were performed using Biotools DNA polymerase (Kordia Life
Sciences) in the provided buffer containing 0.2 mM dNTPs and
1 M betaine. PCR products were purified and sequenced directly
on both strands by use of a CEQ2000 sequencer (Beckman) or
by the Macrogen sequencing service. For the screening of the
118 healthy controls, the region surrounding the deletion was
amplified from genomic DNA with a specific pair of primers (see
Supplementary Table S1). PCR conditions were the same except
that a concentration of 1.5 M betaine was used. The PCR products
were directly loaded on a 2% (w/v) agarose gel containing
0.5 μg/ml ethidium bromide to distinguish wild-type (223 bp)
and mutant (204 bp) alleles.
Neuronal cultures and infection
All experiments with animals have been performed in accordance
with Belgian law and with the agreement of the Ethical Committee
for Animal Experiments of the Faculty of Medicine of the
University of Louvain, Brussels, Belgium. Primary cultures of
cortical neurons were prepared from 17–18-day-old Wistar rat
embryos as described previously [22]. Brains were dissected,
transferred to HBSS (Hanks balanced salt solution) buffer
medium (1 mM sodium pyruvate and 10 mM Hepes, without
Ca2+ and Mg2+), dissociated in the same medium containing
1.26 mM Ca2+ and Mg2+ (0.50 mM MgCl2 and 0.41 mM MgSO4)
and centrifuged for 10 min at 200 g at room temperature.
Cells were plated in culture dishes pre-treated with 10 μg/ml
poly-L-lysine in PBS and cultured for 7 days in neurobasal
medium (Invitrogen) supplemented with 2% (v/v) B-27 medium
(Invitrogen) and 0.5 mM L-glutamine prior to infection with
recombinant lentivirus. The NAT8L–pEF6MycHisA plasmid was
utilized for construction of recombinant lentivirus, as previously
described [23]. After 7 days of culture, neurons were incubated
in the presence of the lentivirus for 3 days before analysis.
Immunofluorescence in transfected CHO (Chinese-hamster ovary)
cells and infected primary neurons
CHO cells were propagated in a DMEM (Dulbecco’s modified
Eagle’s medium)/Ham’s F12 mixture (1:1) supplemented with
10% (v/v) FBS (fetal bovine serum) and antibiotics (100 units/ml
penicillin and 100 μg/ml streptomycin). Cells were seeded at
50000 cells/cm2 in 24-well plates on glass coverslips coated
with 25 μg/μl fibronectin (in PBS) and grown for 1 day (approx.
80% confluency). Transfection with the NAT8L-pEF6MycHisA
plasmid or the PDIb [PDI (protein disulfide isomerase) domain
b]–HA (haemagglutinin) construct [24] was carried out with
0.5 μg of total DNA and 1 μl of Lipofectamine/cm2 at 37 ◦C for
5 h followed by reincubation overnight in DMEM/Ham’s F-12
with 10% (v/v) FBS without antibiotics. After 24 h, cells were
processed for immunofluorescence as described by Mettlen et al.
[25].
For immunofluorescence experiments, neurons were seeded
at 105 cells/cm2 on glass coverslips, fixed with 4% (v/v)
paraformaldehyde for 15 min at room temperature and then
permeabilized with 1% (v/v) Triton X-100 in PBS for 15 min.
Non-specific immunostaining was prevented by blocking for 1 h
in a PBS solution containing 3% (w/v) non-fat dried milk powder
at room temperature.
For primary antibodies, we used a mouse IgG2a anti-Myc
(9B11) monoclonal antibody (Cell Signaling) at a dilution of
1:500, a mouse IgG1 anti-His6 monoclonal antibody (Qiagen)
at a dilution of 1:50, a rabbit affinity-purified specific antibody
against NAT8L at a dilution of 1:100 (see below), a rabbit anti-
HA antibody at a dilution of 1:300 (Roche) or a rat monoclonal
antibody recognizing KDEL-bearing proteins (Abcam) at a
dilution of 1:300, either alone or combined with a mouse IgG2b
monoclonal antibody to PDI (Abcam) at a dilution of 1:50
or a rabbit MAP-2 (microtubule-associated protein-2) primary
antibody (provided by J.-P. Brion, Universite´ Libre de Bruxelles,
Belgium; serum was used at a dilution of 1:1000). Alexa Fluor®-
labelled secondary antibodies (Molecular Probes) were each used
at 5 μg/ml. For live mitochondria labelling, cells were incubated
with 250 nM MitoTracker Red (CMXRos; Molecular Probes) in
DMEM/Ham’s F-12 at 37 ◦C for 30 min followed by a chase
in MitoTracker-free medium for 30 min, before fixation and
permeabilization. All preparations were mounted in Mowiol in the
dark overnight and examined with a LSM 510 META confocal
microscope (Zeiss) using a Plan-Apochromat 63× /1.4 oil DIC
(differential interference contrast) objective.
Specific antibodies against NAT8L
Antibodies were raised against two peptides of mouse
NAT8L (C)NTAFRGLRQHPRTQLL (designated P44) and
(C)MSVDSRFRGKGIAKALG (designated P45) that have
previously been shown to be suitable for immunization [26].
These peptides were conjugated to keyhole-limpet haemocyanin
(Eurogentec) and injected together into rabbits four times at
2-week intervals. Serum was taken from the rabbits 1 month
after the final injection of these peptides. IgGs were bound
to the column in PBS and were isolated from the sera by
affinity chromatography on HiTrapTM Protein G HP columns (GE
Healthcare). IgGs were eluted with 50 mM glycine/HCl, pH 2.7,
containing 150 mM NaCl. Collected fractions were immediately
neutralized with 1 M Tris/HCl, pH 8. Antibodies specific to the
P44 and P45 NAT8L peptides were then purified by affinity
chromatography on columns coupled with the P44 or P45 peptide.
Peptides were coupled through their N-terminal cysteine residue
to iodoacetamide immobilized on a cross-linked agarose support
(Sulfolink; Thermo Scientific Pierce). IgG fractions were loaded
c© The Authors Journal compilation c© 2010 Biochemical Society
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Figure 1 Multiple alignment of NAT8L sequences
The alignment shows the sequences from Homo sapiens [Hsap; NCBI (National Center
for Biotechnology Information) accession number EAW82541], Mus musculus (Mmus;
NCBI accession number NP_001001985) and Danio rerio (Drer; NCBI accession number
NP_001077308). Strictly conserved residues in the three sequences are indicated in bold. A 30
residue hydrophobic region is underlined in the human sequence.
on to the peptide-coupled column in PBS. Antibodies bound
to the column were eluted with 50 mM glycine/HCl, pH 2.7,
containing 150 mM NaCl, and were immediately neutralized with
1 M Tris/HCl, pH 8.
RESULTS
Database searches
The characteristics of Asp-NAT are probably shared by only a
limited number of mammalian gene products. First, this enzyme
most likely belongs to a family of NATs; secondly it is mainly, if
not exclusively, expressed in brain; thirdly it is membrane-bound;
and finally, it should have close homologues only in species that
synthesize NAA. We decided therefore to search mammalian
genomes for genes encoding proteins with these characteristics.
A search in the human and mouse genomes with N-
acetyltransferase as a query yielded about 30 genes. These
comprised a few well-identified sequences (e.g. NATs acting
on arylamines, glucosamine 6-phosphate, glutamate and
spermine/spermidine) but a higher number of putative NATs
(i.e. hypothetical proteins showing sequence similarity to the
well-characterized NATs with undefined specificity). mRNA
expression data from the Symatlas database [27] indicated that
two of these genes were mainly expressed in brain tissue, NAT14
and NAT8L. NAT14, also called Klp1 (K562 cell-derived leucine-
zipper-like protein 1) is thought to be a transcription factor
regulating the expression of coproporphyrinogen oxidase by
binding to a promoter regulatory element [28]. NAT8L, also
designated Shati, is overexpressed in brain after administration
of metamphetamine to mice [26]. Both proteins showed at least
one putative transmembrane domain. Close homologues (of over
50% sequence identity) of NAT8L and NAT14 were only found
in vertebrates. Taken together, these findings indicated that both
NAT8L and NAT14 were good candidates for the Asp-NAT.
Gene structure, tissue distribution and protein sequence analysis
of NAT8L
NAT8L is encoded by a three-exon gene that is on mouse
chromosome 5 and human chromosome 4 (band 4p16.3). Previous
Figure 2 Effect of transfection of HEK-293T cells with mouse NAT8L or
NAT14 on the NAA concentration in the medium and the Asp-NAT activity in
cell extracts
Cells were transfected with plasmids expressing wild-type (WT), a C-terminally His6-tagged
fusion (CT) and a N-terminally (NT) His6-tagged fusion NAT8L or NAT14 protein. Transfection
with an empty plasmid (EP) was used as a control. (A) The indicated extracts were analysed by
Western blot with an anti-His6 antibody to evaluate the level of expression of the recombinant
proteins. A representative blot from three experiments is shown. (B) After 48 h, the NAA
concentration in the medium was measured by GC–MS, and (C) the Asp-NAT activity was assayed
in cell extracts. Results are means +− S.E.M. for three independent transfection experiments.
PCR results obtained with mouse NAT8L indicated that the
mRNA encoding this protein is expressed not only in the brain,
but also in the liver and kidneys [26]. We therefore performed
quantitative PCR amplification (as described in [18]) on mouse
tissue cDNA with pairs of primers situated in exons 1 and 2,
or in exons 2 and 3. Our findings indicated that NAT8L was
amplified from brain cDNA and to a lesser extent from thymus or
spleen cDNA (results not shown). The abundance of the mRNA
was calculated to be approx. 10-fold lower in both these tissues
compared with the brain. No specific amplification was observed
with liver, kidney, lung, skeletal muscle, testis and heart cDNA
(results not shown).
The NAT8L cDNA was also amplified from human brain
cDNA using primers situated in exons 1 and 3. Sequencing of
the amplified product confirmed the predicted protein as the
sequence registered under NCBI accession number EAW82541.
No amplification could be observed in a further experiment with
primers corresponding to a cDNA sequence encoding a protein
(SwissProt accession number Q8N9F0) that differs from human
and mouse NAT8L in the approximately first 90 residues. This
is not surprising as this cDNA in fact contains an exon from an
upstream human gene (LOC401115 in human) fused to exons 2
and 3 of the NAT8L gene (results not shown).
c© The Authors Journal compilation c© 2010 Biochemical Society
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Figure 3 Kinetic properties of the Asp-NAT activity of NAT8L
HEK-293T cells were transfected with untagged mouse NAT8L and the enzymatic activity was determined radiochemically on washed membrane pellets as described in the Experimental section. (A)
Effect of two detergents on the Asp-NAT activity. The assay medium contained 50 μM L-aspartate, 200 μM acetyl-CoA and the indicated concentrations of CHAPS or octylglucoside. (B) Effect of
CHAPS on the saturation curve for acetyl-CoA. Assay medium contained 20 μM L-aspartate and the indicated concentrations of acetyl-CoA and CHAPS. Effect of (C) glutamate and (D) NAA on the
saturation curve for aspartate. Assay medium contained 200 μM acetyl-CoA, 0.5 mM CHAPS and various concentrations of aspartate. (B–D) show double-reciprocal plots. The results shown are
the means +− S.E.M. for three determinations performed with extracts derived from independent transfections. In some cases, the S.E.M. is not visible because it is smaller than the size of the symbol.
The NAT8L sequences of various species are aligned in
Figure 1. As noted previously [26], the C-terminal region is
homologous with NATs. The NAT8L proteins also contain a
conserved N-terminal sequence of 15 residues, a proline- and
alanine-rich region of variable length (residues 40–73 in the
human sequence) and a highly hydrophobic region of approx.
30 amino acids that just precedes the NAT domain.
Targeting prediction programs (TargetP [29] and PSort2 [30])
did not suggest that NAT8L had a mitochondrial propeptide or
a signal peptide. It should also be noted that exon 1 of human,
mouse and rat NAT8L genes contain an in-frame stop codon that
precedes the initiator ATG codon. This indicates that the protein
sequence truly starts with the methionine shown as Met1 in the
alignment. We demonstrate in the next section that NAT14 does
not correspond to Asp-NAT so we have not described its structure
in detail.
Identification of Asp-NAT as NAT8L
Both mouse NAT8L and NAT14 were overexpressed in HEK-
293T cells, either as native proteins or as fusion proteins with
a His6 tag at the C- or the N-terminus. GC–MS analysis
[21] of the medium collected after 48 h indicated the presence
of a product co-eluting with authentic NAA in medium
from the cells transfected with all NAT8L constructs (see
Supplementary Figure S1 available at http://www.BiochemJ.org/
bj/425/bj4250127add.htm), whereas this compound was below
the detection limit of 5 μM in control cells (see Supplementary
Figure S1A) and those transfected with NAT14 constructs. The
fragmentation pattern of this product (see inset of Supplementary
Figure S1B) was identical with that of authentic NAA, with major
fragments having m/z ratios of 73, 147, 184, 245, 274 and 376 [21].
Quantification of NAA by isotope dilution with the trideuterated
compound (Figure 2B) indicated that the concentration of NAA in
the medium amounted to 200–250 μM in cells transfected with the
different NAT8L constructs, corresponding to approx. 300 nmol
per mg of cell protein. Analysis of cell extracts indicated that this
compound was also present intracellularly at concentrations of
approx. 60 nmol/mg of protein (results not shown).
Asp-NAT activity was assayed in cell extracts by monitoring the
acetyl-CoA-dependent conversion of L-[14C]aspartate into a more
acidic product (Figure 2C). Consistent with the results above,
this activity was observed in extracts of cells transfected with the
three types of NAT8L constructs, but not in other extracts. Slightly
lower activities were observed with the N-terminally tagged and
the C-terminally tagged forms when compared with untagged
NAT8L (59% and 75% respectively). Western blot analysis with
an anti-His6 antibody (Figure 2A) revealed that all His6-tagged
versions of NAT8L and NAT14 were expressed. This indicated
that the absence of Asp-NAT activity in cells transfected with
NAT14 was not due to lack of expression of this protein.
Kinetic properties of NAT8L
The Asp-NAT activity was characterized further in extracts
of cells expressing wild-type mouse NAT8L. The enzymatic
activity was almost completely (>90%) recovered in the
pellet after a 20-min centrifugation of frozen/thawed extracts
at 16000 g (results not shown), indicating that NAT8L is
membrane-bound. The kinetic studies were therefore performed
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on washed pellet to eliminate any soluble and potentially
interfering enzymes. Detergents showed a biphasic effect on
the activity (Figure 3A), increasing it at low concentrations,
presumably by allowing access of the catalytic site to substrate,
and being inhibitory at higher concentrations. Double-reciprocal
plots of the saturation curve for aspartate were linear both in
the absence and in the presence of 0.5 mM CHAPS, which
increased Vmax by approx. 30%without affecting the Km (approx.
90 μM) for aspartate (see Supplementary Figure S2 available
at http://www.BiochemJ.org/bj/425/bj4250127add.htm). With
acetyl-CoA as the varying substrate, the double-reciprocal plots
were non-linear in the absence of CHAPS, but linear in its
presence, indicating that part of the enzyme was poorly accessible
to acetyl-CoA in the absence of detergent (Figure 3B). The Km
values were approx. 9 and 13 μM in the presence of 0.5 and 1 mM
CHAPS respectively.
[14C]Glutamate could also act as a substrate for the enzyme,
with an approx. 50-fold lower affinity (Km of approx. 5 mM)
and a similar Vmax compared with aspartate (results not
shown), which is in agreement with previous results [31,32].
Accordingly, the incorporation of [14C]aspartate into NAA was
inhibited by glutamate competitively with respect to aspartate
with a K i of approx. 6 mM (Figure 3C and Supplementary
Figure S3A available at http://www.BiochemJ.org/bj/425/
bj4250127add.htm). No inhibition was observed with other
amino acids, indicating that the enzyme is specific (results not
shown). The enzyme was also inhibited by its reaction product,
NAA. This inhibition was essentially competitive with respect
to aspartate (K i = 0.56 mM; Figure 3D and Supplementary
Figure S3B) and uncompetitive compared with acetyl-CoA (see
Supplementary Figure S4 available at http://www.BiochemJ.org/
bj/425/bj4250127add.htm).
Subcellular localization of NAT8L
As the subcellular localization of Asp-NAT was controversial,
it was of interest to determine the localization of NAT8L in
transfected cells. Confocal microscopy was therefore used to
analyse CHO cells, transfected with C-terminally Myc-tagged,
N-terminally His6-tagged and untagged NAT8L, and neurons
in primary culture, infected with a lentiviral vector allowing
the expression of Myc-tagged NAT8L. Immunolabelling of
Myc-tagged NAT8L expressed in CHO cells or in primary
neurons delineated the nuclear envelope (arrows in Figures 4
and 5) and produced a reticular pattern strongly suggestive of
the ER (endoplasmic reticulum). This was confirmed by the
substantial, although not complete, co-localization of Myc-tagged
NAT8L with KDEL-bearing proteins of the ER (arrowheads
in Figures 4 and 5). Analysis of the colour intensity profiles
in the cytoplasm showed that the peaks of the NAT8L
labelling mostly coincided with the peaks of ER-marker labelling
(Figures 4D and 5C and Supplementary Figure S5C available
at http://www.BiochemJ.org/bj/425/bj4250127add.htm). This
type of co-localization is in keeping with the well-known
heterogeneity among ER domains [33,34]. In contrast, the Myc-
tagged NAT8L signal was fully segregated from the Golgi
complex, recognized by co-transfection with the PDIb–HA
construct [24] (Figure 4B), and from mitochondria labelled in vivo
by MitoTracker Red (Figures 4C and 4E). This latter conclusion
was confirmed by analysis of the intensity profiles (Figure 5B).
Targeting to the nuclear envelope and the ER was independent
of epitope tagging, as NAT8L fused to a Myc tag at its C-
terminus, or to a His6 tag at its N-terminus, showed a similar
localization pattern to native NAT8L recognized with affinity-
purified antibodies (see Supplementary Figure S5A).
Figure 4 Co-localization of Myc-tagged NAT8L with the ER and complete
segregation from the Golgi complex and mitochondria
CHO cells were transfected to express low levels of C-terminally Myc-tagged NAT8L and
immunolabelled with an antibody against a Myc tag (NAT8L-Myc; green the in right-hand
merge column). (A) Double immunolabelling for KDEL-bearing proteins to label the ER (red
in the right-hand merge column). (B) Cells were co-transfected with the PDIb–HA construct
to immunolabel the Golgi apparatus (red in right-hand merge column). (C) Transfected cells
were incubated with MitoTracker Red before fixation to label the mitochondria (mito; red in
the right-hand merge column). Notice the nuclear envelope labelling by NAT8L (arrows in the
middle images) and its reticular pattern in the cytoplasm with substantial co-localization with
the ER marker (arrowheads), contrasting with full segregation from Golgi and mitochondrial
labelling. Scale bars, 5 μm. (D and E) Intensity profiles along the paths indicated by the broken
arrows in the right-hand images of (A) and (C) respectively.
Mutation of NAT8L in a patient with hypoacetylaspartia
To determine whether NAT8L was mutated in the patient deficient
in NAA, we amplified the three exons of the NAT8L gene and
screened them for mutations. A 19-bp deletion in the homozygous
form was observed in the first exon (Figure 6A). This mutation
leads to a change in the reading frame after amino acid 69
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Figure 5 Co-localization of Myc-tagged NAT8L with ER and its segregation from mitochondria in neurons
Primary cultures of rat fetal neurons were infected with lentiviruses encoding C-terminally Myc-tagged NAT8L, fixed at a low level of expression and immunolabelled for the Myc antigen (NAT8L-Myc,
green in the merge column). (A) Triple immunolabelling against ER markers (KDEL combined with PDI antibodies, red in the merge column) and MAP-2 to establish neuronal identity (blue). (B)
Neurons were incubated with MitoTracker Red (red in the merge column), then immunolabelled for Myc antigen (green in the merge column) and MAP-2 (blue). The complete delineation of the
nuclear envelope by NAT8L is best seen in the upper panel as indicated by the arrows, which is also evidence for the same reticular pattern as for ER markers. In neurons, MitoTracker Red is known
to produce much weaker signals than in CHO cells, yet it is also clearly segregated from NAT8L. Scale bars, 5 μm. (C) Intensity profile along the path indicated by the broken arrow in the merge
image of (A).
and therefore it would be expected that no functional protein
is produced. To rule out the possibility that this mutation would
still allow the production of an active protein by codon-slipping or
by reinitiation at a later AUG codon, we prepared an expression
vector for this mutated form (with a C-terminal His6 tag) and
transfected it into HEK-293T cells. Extracts prepared from these
cells did not contain any detectable Asp-NAT activity or material
reacting with the anti-His6 antibody, whereas extracts of cells
transfected with the unmutated human cDNA were enzymatically
active and contained an immunoreactive band of the appropriate
size (Figures 6B and 6C).
Several human NAT8L protein entries (e.g. Ensembl accession
number BAC04426.1) comprise only the last 134 amino acids
of NAT8L. The sequence of this putative shorter protein(s) is
unaffected by the mutation and it was therefore important to
verify whether it displayed Asp-NAT activity. Transfection of a
vector allowing the expression of this shorter form resulted in the
expression of a polypeptide of the expected size (approx. 18 kDa)
but with no detectable enzymatic activity (Figures 6B and 6C).
Taken together, these findings indicated that the mutation found
in the patient indeed corresponds to a null mutation.
The patient is an adopted child and no material was therefore
available to ascertain the presence of the mutation in the biological
parents. The mutation found in the patient could be detected by
PCR amplification of genomic DNA and gel electrophoresis.
This assay allowed also the detection of the mutation in the
heterozygous state, as indicated by amplifications performed on
samples containing equal amounts of DNA from the patient
and a control. The 19 bp deletion was not found in 118 control
DNA samples either in the homozygous or the heterozygous state
(results not shown).
DISCUSSION
Molecular identification of Asp-NAT
Despite its discovery about 50 years ago [2], Asp-NAT had not
yet been identified molecularly due to the difficulty of purifying
this membrane-bound enzyme [7]. The availability of databases
comprising virtually all proteins encoded by the human and
mouse genomes, and those providing information on their tissue
distribution, enabled us to identify two candidate proteins for
this enzyme. Transfection studies in HEK-293T cells showed
that NAT8L-expressing cells synthesize NAA and that extracts of
these cells display Asp-NAT activity. This activity had properties
similar to those of brain Asp-NAT, including its Km value for
aspartate, its specificity for this amino acid, its inhibition by the
reaction product, its association with membranes and its inhibition
by detergents [4,5,7,32]. These findings therefore indicate that
NAT8L protein is responsible for NAA synthesis in brain. This
conclusion is strongly supported by the finding that the NAT8L
gene is mutated in the only patient reported to have undetectable
levels of NAA in brain. Considering that NAA is restricted
to neurons, where it is synthesized, our identification is also
consistent with immunohistochemical studies showing that mouse
NAT8L (the Shati protein) is exclusively present in neurons [26].
As expected for Asp-NAT, close homologues of NAT8L were
found in vertebrates, whose brain contains NAA, but not in insects
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Figure 6 Analysis of the mutation found in the patient with
hypoacetylaspartia and its effect on the activity and expression of NAT8L
(A) Sequences of nucleotides 190–240 (nucleotide 1 corresponds to the adenine of the initiator
ATG codon) of the NAT8L open reading frame and the deduced protein sequences in controls
(Cl) and in the patient (Pt). The 19 nucleotides deleted in the patient are shown in lowercase
characters and the 11 bp repeats between which this deletion occurred is underlined. (B and C)
HEK-293T cells were transfected with an empty plasmid (EP) or a plasmid driving the expression
of human wild-type NAT8L (Met1), the form with the 19 bp deletion (del19) and a shorter form
corresponding to amino acids 169–302 (Met169). All proteins contained a C-terminal His6 tag.
(B) Asp-NAT activity in cell extracts. (C) Western blots with an anti-His6 antibody.
and Caenorhabditis elegans, where NAA has never been reported.
Unfortunately, the genome of the crayfish, in which NAA has been
described [35], has not yet been sequenced.
Molecular basis of hypoacetylaspartia
The finding that the NAT8L gene is mutated in the single known
case of hypoacetylaspartia [15–17] indicates that this disorder, in
which no NAA is detectable in brain, is due to a lack of synthesis of
this compound in brain. This excludes other potential causes, such
as an increased degradation by a hyperactive aspartoacylase, or
a deficiency in the transport or the formation of aspartate and/or
acetyl-CoA in the compartment in which Asp-NAT is present.
The finding that this mutation induces a change in reading frame
indicates a null mutation. Accordingly, no NAA synthase activity
could be detected in cells that had been transfected with a plasmid
carrying this mutated allele.
The homozygous mutation found in the patient suggests that he
may be the offspring of consanguineous parents. Unfortunately,
no information is available on the biological parents. Therefore
one has to be very cautious before concluding that the phenotype
of this unique patient is representative of hypoacetylaspartia, as
he may suffer from other recessive genetic diseases.
It is likely that hypoacetylaspartia is under-diagnosed for two
reasons. First, MRS is not systematically performed to investigate
neurological problems in young children. Secondly, decreased
levels of NAA are usually interpreted as being secondary to a loss
of neuronal integrity, rather than as a primary cause of neuronal
dysfunction. However, point mutations in the NAT8L gene that
would not lead to a complete loss of enzymatic activity could
result in low, yet detectable, levels of NAA and be associated
with milder forms of the disease than that described in the only
patient known so far. It would therefore be of interest to determine
more systematically the brain NAA level in young patients with
mental retardation, epilepsy of unknown origin and/or ataxia,
and to search the NAT8L gene for mutations if the NAA level is
decreased.
Subcellular localization of Asp-NAT
As mentioned in the Introduction, the subcellular localization of
Asp-NAT is still a matter of controversy. Fractionation studies
of brain extracts have variously concluded a microsomal [4]
or mitochondrial localization of Asp-NAT [6,7]. However, one
of the studies concluding a mitochondrial localization in fact
shows that the specific activity of Asp-NAT is higher in the
microsomal than in the mitochondrial fraction [7], which argues
for a microsomal localization. The finding that purified brain
mitochondria produce NAA when incubated with glutamate (a
source of aspartate) and pyruvate (a source of acetyl-CoA in
the mitochondrial matrix) is taken as evidence that intact brain
mitochondria contain Asp-NAT [6]. One has to note, however,
that the assay used by Patel and Clark [6] for measuring the
NAA produced by mitochondria employed a rather crude (7-fold
purified) preparation of kidney aspartoacylase from pig to convert
NAA into aspartate. Therefore another metabolite (asparagine,
for instance) may have been measured. These contradictory
findings are most probably the result of the inherent difficulty
of studying the subcellular distribution by fractionation in such a
heterogeneous tissue as brain.
Recent tracer studies comparing the incorporation of radio-
activity into NAA from L-aspartate and L-malate in a neuro-
blastoma cell line have led Arun et al. [36] to conclude that
mitochondria are a major site of NAA synthesis. However, the
TLC technique used to isolate radiolabelled NAA and L-aspartate
does not allow one to separate these metabolites from other
radioactive metabolites, which certainly form when cells are
incubated for 3 h with a radioactive precursor, meaning the results
of this work have to be interpreted with caution.
Low levels of NAA have been reported in the brains of mice
deficient in Aralar (also known as Slc25a12, solute carrier family
25 member 12) [37], a glutamate/aspartate exchanger serving
to export aspartate from brain mitochondria. This was taken to
suggest that aspartate has to be transferred from the mitochondria
to the cytosol before being acetylated by Asp-NAT. This argument,
although suggestive against a mitochondrial localization of Asp-
NAT, is not decisive because one may not exclude that a defect in
Aralar also causes a decrease in the mitochondrial concentration
of aspartate.
The results from present study on the localization of NAT8L
indicate that this protein does not co-localize with mitochondria,
consistent with the absence of a mitochondrial propeptide in the
NAT8L sequence. The pattern of the expression with labelling
of the nuclear membrane and the, at least partial, co-localization
with ER markers, indicate instead that NAT8L is associated with
the ER. This localization is independent of the tagging used and
is observed not only in CHO cells, but also in neurons in primary
cultures. Therefore these findings lead us to conclude that Asp-
NAT is associated with the ER.
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Conclusion
The results from the present study opens up the possibility of de-
veloping new experimental models to better define the role of
NAA. None of the roles proposed so far accounts for the very high
concentration of NAA in neurons, as NAA does not appear to be
a neurotransmitter [13] and its role as an osmolyte is at best very
minor compared with that of other solutes present in neural cells
[38]. The role of NAA in myelination may even be questioned as
this process is only moderately delayed in the patient with NAA
deficiency [16,17]. The creation of a mouse knockout model may
also help define which of the symptoms found in the patient
with hypoacetyaspartia truly are due to the NAA deficiency. The
availability of the Asp-NAT sequence will also allow for a better
definition of the mechanisms that control the concentration of
this compound, including the effect of pathological conditions
[39] and antipsychotic drugs [40]. In this respect, the finding
that NAT8L/Shati is up-regulated following metamphetamine
treatment suggests that NAA plays a role, presumably an
indirect one, in dopaminergic transmission [26,41]. The present
study also suggests that it might be more widely necessary
to perform MRS in children with developmental problems,
especially when microcephaly is present, to check for NAA
deficiency.
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Figure S1 GC–MS analysis of the product released in the culture medium of cells expressing NAT8L
Selected–ion mode chromatogram at m/z=274 of the trimethylsilyl derivatives found in the medium of (A) control cells and (B) cells transfected with a plasmid encoding untagged mouse NAT8L.
The inset shows the mass spectrum of the peak eluting at 9.18 min, matching that of the trimethylsilyl derivative of commercial NAA (not shown). These results are representative of results obtained
with medium from three independent transfections.
1 To whom correspondence should be addressed (email emile.vanschaftingen@uclouvain.be).
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Figure S2 Double-reciprocal plot of the saturation curve for aspartate in
the absence or presence of CHAPS
HEK cells were transfected with untagged mouse NAT8L and the enzymatic activity was
determined radiochemically on washed membrane pellets as described in the Experimental
section of the main paper. The assay medium contained 200 μM acetyl-CoA and the
indicated concentrations of aspartate and CHAPS. Results represent means +− S.E.M. for three
determinations performed with extracts from three independent transfections. In some cases,
the S.E.M. is not visible because it is smaller than the size of the symbol.
Figure S3 Plot of the apparent Km for aspartate as a function of the
concentration of glutamate and NAA
The apparent K m values were calculated from the double-reciprocal plots shown in (A) Figure
3(C) in the main paper for glutamate and (B) Figure 3(D) in the main paper for NAA. Competitive
inhibition constants (K i) of 6.1 mM and 0.56 mM were calculated for glutamate and NAA from
the intercepts with the x-axis.
Figure S4 Double-reciprocal plot of the saturation curve for acetyl-CoA in
the presence of NAA
HEK cells were transfected with untagged mouse NAT8L and the enzymatic activity was
determined radiochemically on washed membrane pellets as described in the Experimental
section in the main paper. The assay medium contained 50 μM aspartate, 0.5 mM CHAPS and
the indicated concentrations of acetyl-CoA and NAA. Means +− S.E.M. for four determinations
performed with extracts from four independent transfections.
Figure S5 Identical distribution in CHO cells of untagged, Myc-tagged and
His6-tagged NAT8L
(A) Cells were co-transfected for expression of untagged NAT8L and either the C-terminally
Myc-tagged NAT8L (upper panels) or the N-terminally His6-tagged NAT8L (lower panels).
Double immunolabelling was performed using affinity-purified antibodies against NAT8L (green)
and monoclonal anti-Myc or anti-His6 antibodies (red) and shows extensive co-localization,
with a reticular pattern. (B) Cells were transfected with native (upper panels) or N-terminally
His6-tagged NAT8L (lower panels), then double-immunolabelled either with affinity-purified
antibodies against NAT8L (upper panels) or anti-His6 antibody (lower panels) in green, together
with antibodies against KDEL-bearing proteins (KDEL; red). The reticular pattern of both NAT8L
constructs largely overlaps with the ER marker. Scale bars, 5μm. (C) Intensity profile along the
path indicated by the broken arrow in (B).
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Table S1 Sequences of primers used in PCR and sequencing experiments
The human NAT8L expression vectors were prepared with the same couples of primers as that used for mouse given the nucleotide sequence of the human and the mouse NAT8L genes are identical
at both ends.
Sequence of the forward primer Sequence of the reverse primer
Preparation of mouse NAT14 and NAT8L expression vectors
couple 1 (untagged NAT14) 5′-GGGTACCCCCGCCGCCACCATGGCCCCTAACCACCTG-3′ 5′-TTCTAGATCACAGGTCTTTGCTGAATTCC-3′
couple 2 (C-teminally tagged NAT14) 5′-GGGTACCCCCGCCGCCACCATGGCCCCTAACCACCTG-3′ 5′-TTCTAGACAGGTCTTTGCTGAATTCCCTA-3′
couple 3 (N-teminally tagged NAT14) 5′-GGGTACCCATGGCCCCTAACCACCTG-3′ 5′-TTCTAGATCACAGGTCTTTGCTGAATTCC-3′
couple 4 (untagged NAT8L) 5′-GGGTACCCCCGCCGCCACCATGCATTGTGGGCCTCCCGAC-3′ 5′-GTCTAGATCACTCCTCGCGCAGCTGCAGG-3′
couple 5 (C-teminally tagged NAT8L) 5′-GGGTACCCCCGCCGCCACCATGCATTGTGGGCCTCCCGAC-3′ 5′-GTCTAGACTCCTCGCGCAGCTGCAGG-3′
couple 6 (N-teminally tagged NAT8L) 5′-GGGTACCCATGCATTGTGGGCCTCCCGAC-3′ 5′-GTCTAGATCACTCCTCGCGCAGCTGCAGG-3′
Site-directed mutagenesis
couple 7 (deletion of nucleotides 212–230) 5′-CGTGTGCATCCGCGAGTTCC-3′ 5′-CCGCGCCCCCCGCCCCGCCG-3′
couple 8 (deletion of nucleotides 1–504) 5′-ATGGCGGACATCGAGCAGTACTA-3′ 5′-GGTGGCGGCGGGGGTACCCA-3′
Mutation search
couple 9 (exon 1) 5′-TTGCCCTGGGCCCGGCCGT-3′ 5′-AGGCCGTGTTAGGGATGCGCTC-3′
couple 10 (exon 1) 5′-TTGCCCTGGGCCCGGCCGT-3′ 5′-CACGCCCATAGCCAGCCCTGC-3′
couple 11 (exon 2) 5′-GTCCCTAGCGGGCTTCGCC-3′ 5′-TGCCCTGAGGTCGCTGGAGTG-3′
couple 12 (exon 3) 5′-TGTCTCACCCCAGAGGTGGAG-3′ 5′-CCAATTGAGCGTCTGAAAGCAGG-3′
couple 13 (controls for screening) 5′-CAAGAAGGACGCGCTGCTCG-3′ 5′-CATGATGCCGTCGTAGAAGATG-3′
Amplification of the human cDNA
couple 14 5′-CTGAGTTCACGGGACTGAAATC-3′ 5′-CACCTTGCGGCTGTAGTAGTAG-3′
couple 15 5′-CTGAGTTCACGGGACTGAAATC-3′ 5′-CCAGCGACTCGTAGAGCTTG-3′
couple 16 5′-GAGTTCATGCAGCGCGCCCT-3′ 5′-CACCTTGCGGCTGTAGTAGTAG-3′
couple 17 5′-GAGTTCATGCAGCGCGCCCT-3′ 5′-CCAGCGACTCGTAGAGCTTG-3′
couple 18 5′-GACATGGTCTGCGAGACGAAG-3′ 5′-CACCTTGCGGCTGTAGTAGTAG-3′
couple 19 5′-GACATGGTCTGCGAGACGAAG-3′ 5′-CCAGCGACTCGTAGAGCTTG-3′
Quantitative real-time PCR
couple 20 5′-CCGCATCTTCTACGACGG-3′ 5′-CGCACACTCCAGGTAGGC-3′
couple 21 5′-TACTACTACAGCCGCAAGG-3′ 5′-GCGAGTCCACGGACATGC-3′
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